Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial
Authors
Keywords
-
Journal
Lancet Gastroenterology & Hepatology
Volume 6, Issue 9, Pages 723-732
Publisher
Elsevier BV
Online
2021-07-06
DOI
10.1016/s2468-1253(21)00176-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug
- (2021) Valérie Cosson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- JNJ-56136379, an HBV Capsid Assembly Modulator, is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection
- (2020) Fabien Zoulim et al. GASTROENTEROLOGY
- A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants
- (2020) Sheng Feng et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- PS-156-Antigen suppression effect of the core protein allosteric modulator R07049389 in AAV-HBV mice is accompanied by transient upregulation of immune-cell gene signatures in the liver
- (2019) Xue Zhou et al. JOURNAL OF HEPATOLOGY
- BAY 41-4109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy
- (2019) Virgile Rat et al. ANTIVIRAL RESEARCH
- Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
- (2019) Man-Fung Yuen et al. Lancet Gastroenterology & Hepatology
- Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro
- (2018) Angelica Corcuera et al. ANTIVIRAL RESEARCH
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
- (2018) Norah A. Terrault et al. HEPATOLOGY
- In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule capsid assembly modulator for the treatment of chronic hepatitis B
- (2018) X. Zhou et al. JOURNAL OF HEPATOLOGY
- Hepatitis B virus infection
- (2018) Man-Fung Yuen et al. Nature Reviews Disease Primers
- Hepatitis B core protein as a therapeutic target
- (2017) Lung-Yi Mak et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Hepatitis B cure: From discovery to regulatory approval
- (2017) Anna S. Lok et al. HEPATOLOGY
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
- (2017) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- Core protein: A pleiotropic keystone in the HBV lifecycle
- (2015) Adam Zlotnick et al. ANTIVIRAL RESEARCH
- Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
- (2015) Kosh Agarwal et al. JOURNAL OF HEPATOLOGY
- High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein
- (2015) Klaus Klumpp et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management
- (2014) Ming-Ling Chang et al. JOURNAL OF HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now